Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscular Dystrophy - Overview
Muscular Dystrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Muscular Dystrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscular Dystrophy - Companies Involved in Therapeutics Development
Muscular Dystrophy - Drug Profiles
Muscular Dystrophy - Dormant Projects
Muscular Dystrophy - Discontinued Products
Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Oct 14, 2022: Avidity Biosciences announces upcoming presentation on AOC-1001 at 27th Intertiol Hybrid Annual Congress of World Muscle Society
Oct 14, 2022: Avidity Biosciences announces upcoming presentation on AOC-1001 at 27th Intertiol Hybrid Annual Congress of World Muscle Society
Sep 28, 2022: FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial
Sep 27, 2022: Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
Aug 04, 2022: Entrada Therapeutics announces collaboration with the Myotonic Dystrophy Clinical Research Network to study the tural history of myotonic dystrophy type 1
Aug 02, 2022: Avidity Biosciences enrolls patients in the MARI open-label extension study
Jul 13, 2022: Fulcrum phase 3 FSHD clinical trial using AMRA Medical’s Whole-body MRI Measurements as a Key Secondary Endpoint
Jul 12, 2022: Dyne Therapeutics announces clearance of clinical trial application for DYNE-101 for the treatment of myotonic dystrophy type 1
Jul 05, 2022: Fulcrum Therapeutics enrolls first patient in pivotal global Phase 3 clinical trial of Losmapimod for facioscapulohumeral muscular dystrophy (FSHD)
Jun 20, 2022: New muscle disease indication for ATL1102 - Limb girdle muscular dystrophy R2
May 17, 2022: NeuBase presents new preclinical data at ASGCT 2022 for its DM1 program demonstrating wide tissue distribution and supporting a differentiated whole-body treatment solution
May 16, 2022: Dyne Therapeutics presents new in vivo data from DYNE-101 at ASGCT Annual Meeting demonstrating low monthly dosing leads to robust DMPK R knockdown
May 16, 2022: Atamyo Therapeutics announces significant for ATA-100 to treat Limb-Girdle Muscular Dystrophy 2I/R9
May 11, 2022: Entrada Therapeutics presents new data supporting its growing pipeline of Endosomal Escape Vehicle (EEV?) therapeutics, including ENTR-701 at TIDES USA 2022
May 02, 2022: NeuBase Therapeutics announces presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Muscular Dystrophy - Dormant Projects, 2022
Muscular Dystrophy - Dormant Projects, 2022 (Contd..1)
Muscular Dystrophy - Dormant Projects, 2022 (Contd..2)
Muscular Dystrophy - Dormant Projects, 2022 (Contd..3)
Muscular Dystrophy - Discontinued Products, 2022